Literature DB >> 11160862

Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1.

D Siegel1, A Anwar, S L Winski, J K Kepa, K L Zolman, D Ross.   

Abstract

The NAD(P)H:quinone oxidoreductase 1 (NQO1)*2 polymorphism is characterized by a single proline-to-serine amino acid substitution. Cell lines and tissues from organisms genotyped as homozygous for the NQO1*2 polymorphism are deficient in NQO1 activity. In studies with cells homozygous for the wild-type allele and cells homozygous for the mutant NQO1*2 allele, no difference in the half-life of NQO1 mRNA transcripts was observed. Similarly, in vitro transcription/translation studies showed that both wild-type and mutant NQO1 coding regions were transcribed and translated into full-length protein with equal efficiency. Protein turnover studies in NQO1 wild-type and mutant cell lines demonstrated that the half-life of wild-type NQO1 was greater than 18 h, whereas the half-life of mutant NQO1 was 1.2 h. Incubation of NQO1 mutant cell lines with proteasome inhibitors increased the amount of immunoreactive NQO1 protein, suggesting that mutant protein may be degraded via the proteasome pathway. Additional studies were performed using purified recombinant NQO1 wild-type and mutant proteins incubated in a rabbit reticulocyte lysate system. In these studies, no degradation of wild-type NQO1 protein was observed; however, mutant NQO1 protein was completely degraded in 2 h. Degradation of mutant NQO1 was inhibited by proteasome inhibitors and was ATP-dependent. Mutant NQO1 incubated in rabbit reticulocyte lysate with MG132 resulted in the accumulation of proteins with increased molecular masses that were immunoreactive for both NQO1 and ubiquitin. These data suggest that wild-type NQO1 persists in cells whereas mutant NQO1 is rapidly degraded via ubiquitination and proteasome degradation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160862     DOI: 10.1124/mol.59.2.263

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  66 in total

1.  DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma.

Authors:  Christopher M Cabello; Sarah D Lamore; Warner B Bair; Angela L Davis; Sara M Azimian; Georg T Wondrak
Journal:  Free Radic Res       Date:  2010-11-01

2.  E3 ligase STUB1/CHIP regulates NAD(P)H:quinone oxidoreductase 1 (NQO1) accumulation in aged brain, a process impaired in certain Alzheimer disease patients.

Authors:  Peter Tsvetkov; Yaarit Adamovich; Evan Elliott; Yosef Shaul
Journal:  J Biol Chem       Date:  2011-01-10       Impact factor: 5.157

3.  NQO1 regulates mitotic progression and response to mitotic stress through modulating SIRT2 activity.

Authors:  Hong-Jun Kang; Ha Yong Song; Mohamed A Ahmed; Yang Guo; Mingming Zhang; Chuyu Chen; Massimo Cristofanilli; Dai Horiuchi; Athanassios Vassilopoulos
Journal:  Free Radic Biol Med       Date:  2018-08-13       Impact factor: 7.376

4.  Genetic variants in metabolizing genes NQO1, NQO2, MTHFR and risk of prostate cancer: a study from North India.

Authors:  Raju K Mandal; Kamran Nissar; Rama D Mittal
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

5.  Catechol-O-methyltransferase: effects of the val108met polymorphism on protein turnover in human cells.

Authors:  Anne E Doyle; James D Yager
Journal:  Biochim Biophys Acta       Date:  2007-10-16

6.  Human betaine-homocysteine methyltransferase (BHMT) and BHMT2: common gene sequence variation and functional characterization.

Authors:  Fang Li; Qiping Feng; Candace Lee; Shuzhan Wang; Linda L Pelleymounter; Irene Moon; Bruce W Eckloff; Eric D Wieben; Daniel J Schaid; Vivien Yee; Richard M Weinshilboum
Journal:  Mol Genet Metab       Date:  2008-05-23       Impact factor: 4.797

7.  Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer.

Authors:  Joanna Szkandera; Gudrun Absenger; Nadia Dandachi; Peter Regitnig; Sigurd Lax; Michael Stotz; Hellmut Samonigg; Wilfried Renner; Armin Gerger
Journal:  Mol Genet Genomics       Date:  2012-08-18       Impact factor: 3.291

8.  Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to radiation-induced myeloproliferative disease.

Authors:  Karim Iskander; Roberto J Barrios; Anil K Jaiswal
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

9.  NAD(P)H quinone oxidoreductase protects TAp63gamma from proteasomal degradation and regulates TAp63gamma-dependent growth arrest.

Authors:  Oshrat Hershkovitz Rokah; Ofer Shpilberg; Galit Granot
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

10.  NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.

Authors:  Seema Singh; Muhammad Zahid; Muhammad Saeed; Nilesh W Gaikwad; Jane L Meza; Ercole L Cavalieri; Eleanor G Rogan; Dhrubajyoti Chakravarti
Journal:  J Steroid Biochem Mol Biol       Date:  2009-07-21       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.